LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that it has entered into an agreement to acquire from Eli Lilly and Company (NYSE: LLY) all rights in the U.S. and Canada to manufacture, market and sell the lyophilized antibiotic Capastat® Sulfate (capreomycin for injection, USP). Akorn will own the Capastat NDA and expects to launch the product in the third quarter of this year.
